Frontlight ResearchEarly access
Not yet taking people in United StatesNo phase
Protocol CAUSE-05 RHINO
Key facts
- Who runs it
- National Institute of Allergy and Infectious Diseases (NIAID)
- Where
- Chicago, Cincinnati, and St Louis, United StatesSee the 3 sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 60 people, planned
- Starts
- 3 Dec 2026
- Expected to end
- 28 Sept 2027
- Type of study
- Observational
- Record updated
- 16 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Able to understand and provide informed consent
- Age 18 years or older
- Currently pregnant, with:; Gestational age ≥ 28 weeks as confirmed by participant self-report; Intent to deliver at a participating clinical site labor and delivery (L\&D) center
- Agrees to enroll infant into the study at birth
- In the case of multiple gestation, agrees to enroll only one infant who will be randomly selected
- Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the Protocol CAUSE-05 (RHINO) Manual of Procedures (MOP) a. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion
Who cannot take part
- Diagnosed at birth with any medical condition which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the family's ability to comply with the protocol, or may impact the interpretation of data obtained from the study
- Known plans to move outside the pre-selected recruitment census tracts before the infant reaches 4 months of age
- Inability or unwillingness to give written informed consent or comply with study protocol
- Insufficient proficiency in English or Spanish to provide informed consent and complete study procedures
- Obstetric complications present and/or anticipated that could, in the opinion of the investigator, impact the study objectives
- Pregnancy conceived via donor oocyte (egg donation)
- Intent to transfer infant custody (e.g., via adoption or foster placement) within 4 months of birth
- Past or current medical problems that are not listed above, which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the participant's ability to comply with the protocol, or may impact the interpretation of data obtained from the study; Infants who meet any of the following criteria at the Birth Visit are not eligible for further study participation:
- Delivery before 36 weeks gestation
Where in United States
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesContact: Sarah GodleyNot yet recruiting
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Molly Brausch-BradnerNot yet recruiting
- Washington University at St. LouisSt Louis, United StatesContact: Gina SimpsonNot yet recruiting
About the trial
What the trial wants to find out
CAUSE-05/RHINO is an observational study designed to learn how babies' nasal cells grow and change during the first months of life. The study will enroll pregnant mothers in their third trimester and their infants upon delivery for a target population of 60 mother-baby pairs. Researchers will conduct up to 6 study visits and collect serial nasal samples through 4 months of age.
The group in the trial
- Pregnant females 18 years and older and their infants upon delivery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Respiratory Health & Infant Nasal 'Omics (RHINO) (CAUSE-05)
- Record updated
- 16 November 2026